RFP
MYGN icon

Root Financial Partners’s Myriad Genetics MYGN Stock Holding History

Root Financial Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.01K Buy
+224
New +$1.17K ﹤0.01% 2613

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Root Financial Partners's MYGN Position: Q1 2026 in Review

Root Financial Partners opened a new position in Myriad Genetics (MYGN) in Q1 2026: 224 shares worth $1.01K. The stake represents ﹤0.01% of the portfolio and ranks #2613 among its holdings.

202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Root Financial Partners held 224 shares of Myriad Genetics worth $1.01K as of Q1 2026.
  • Myriad Genetics was a new Root Financial Partners position in Q1 2026.
  • Myriad Genetics made up ﹤0.01% of Root Financial Partners's portfolio in Q1 2026, its #2613 holding.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Root Financial Partners's 13F filing for Q1 2026, filed 24 Apr 2026.